Athenex is a global oncology focused biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, aiming to develop safer and more efficacious cancer medication.
Founded in 2003 and based in Buffalo, New York, our mission is to improve the lives of cancer patients by creating more effective, safer and tolerable treatments. Our current clinical pipeline is derived from four different platform technologies: (1) Orascovery, based on P-glycoprotein inhibitor, (2) Src kinase inhibition, (3) Cell Therapy, and (4) Arginine deprivation therapy. Athenex’s employees worldwide are dedicated to improving the lives of cancer patients by creating more active and tolerable treatments. Read more »
Athenex Announces MHRA Decision on Oral Paclitaxel
Athenex Exits 503B Sterile Compounding Business
Athenex Announces Positive Results of Special Stockholder Meeting